Ex vivo permeation of erythropoietin through porcine conjunctiva, cornea, and sclera

[1]  P. Miller,et al.  Slatter's Fundamentals of Veterinary Ophthalmology , 2017 .

[2]  R. Munisvaradass,et al.  Revisiting the role of erythropoietin for treatment of ocular disorders , 2016, Eye.

[3]  E. Delgado,et al.  Ocular Erythropoietin Penetration after Subconjunctival Administration in Glaucomatous Rats , 2016, Ophthalmic Research.

[4]  K. Falavarjani,et al.  Erythropoietin in ophthalmology: A literature review. , 2016 .

[5]  I. Rupenthal,et al.  In vitro and ex vivo corneal penetration and absorption models , 2016, Drug Delivery and Translational Research.

[6]  P. Govoni,et al.  Permeation of proteins, oligonucleotide and dextrans across ocular tissues: experimental studies and a literature update. , 2015, Journal of pharmaceutical sciences.

[7]  F. Wang,et al.  The Protective Effect of Erythropoietin on the Retina , 2015, Ophthalmic Research.

[8]  T. Rex,et al.  Evidence That Erythropoietin Modulates Neuroinflammation through Differential Action on Neurons, Astrocytes, and Microglia , 2014, Front. Immunol..

[9]  Mark R Prausnitz,et al.  Ocular delivery of macromolecules. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[10]  J. Jordán,et al.  Advances in the understanding of retinal drug disposition and the role of blood–ocular barrier transporters , 2013, Expert opinion on drug metabolism & toxicology.

[11]  E. Delgado,et al.  Alternative route for erythropoietin ocular administration , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.

[12]  S. K. Li,et al.  Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab. , 2013, Journal of pharmaceutical sciences.

[13]  A. Loewenstein,et al.  Drug Delivery to the Posterior Segment of the Eye , 2011, European journal of ophthalmology.

[14]  J. Fisher.  Landmark advances in the development of erythropoietin , 2010, Experimental biology and medicine.

[15]  P. Govoni,et al.  In‐vitro permeation of bevacizumab through human sclera: effect of iontophoresis application , 2010, The Journal of pharmacy and pharmacology.

[16]  A. Nugent,et al.  Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. , 2009, Investigative ophthalmology & visual science.

[17]  M. Bach,et al.  Feasibility of intravitreal erythropoietin injections in humans , 2009, British Journal of Ophthalmology.

[18]  Y. Cheng,et al.  Erythropoietin with retrobulbar administration protects retinal ganglion cells from acute elevated intraocular pressure in rats. , 2008, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[19]  S. Krishnakumar,et al.  Nanotechnology in ocular drug delivery. , 2008, Drug discovery today.

[20]  P. Campochiaro,et al.  Trans-scleral delivery of antiangiogenic proteins. , 2008, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[21]  Y. Cheng,et al.  Promotion of neurite outgrowth and protective effect of erythropoietin on the retinal neurons of rats , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[22]  F. Tomasello,et al.  The role of erythropoietin in neuroprotection: therapeutic perspectives. , 2007, Drug news & perspectives.

[23]  S. Dunlop,et al.  Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection , 2007, Experimental Neurology.

[24]  John Bradley,et al.  Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. , 2007, Investigative ophthalmology & visual science.

[25]  E. Corsini,et al.  Erythropoietin: a novel neuroprotective cytokine. , 2005, Neurotoxicology.

[26]  Vincent H L Lee,et al.  Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[27]  M. Forbes,et al.  Intravitreal Administration of Erythropoietin and Preservation of Retinal Ganglion Cells in an Experimental Rat Model of Glaucoma , 2005, Current eye research.

[28]  L. Remington.  Chapter 2 – Cornea and Sclera , 2005 .

[29]  F. A. Neto,et al.  Recombinant human erythropoietin in sports: a review , 2003 .

[30]  S. Koevary.  Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. , 2003, Current drug metabolism.

[31]  Ivana K. Kim,et al.  Diffusion of high molecular weight compounds through sclera. , 2000, Investigative ophthalmology & visual science.

[32]  G. K. Wong,et al.  DEVELOPMENT AND VALIDATION OF IN VITRO RELEASE TESTING METHODS FOR SEMISOLID FORMULATIONS , 1993 .

[33]  R. Dreyer,et al.  Ophthalmic anatomy. , 1982, Primary care.

[34]  M. Lemp.  Cornea and sclera. , 1973, Archives of ophthalmology.